Blood Podcast Review Series on Follicular Lymphoma
17 snips
Oct 30, 2025 Join Dr. Sarah C. Rutherford, a lymphoma specialist, Dr. Carla Casulo, a clinician-scientist tackling relapsed follicular lymphoma, and Dr. Aaron Perry, a researcher focused on lymphoma biology. They delve into innovative treatment strategies like bispecific antibodies and CAR T-cell therapies. The conversation explores personalizing therapies based on patient history, the biology behind lymphoma transformation, and how emerging tools like ctDNA can guide treatment choices. Plus, they discuss the potential for cures and the complexities of managing high-risk cases.
AI Snips
Chapters
Transcript
Episode notes
Bispecifics And CAR T Reshape Relapse Care
- Bispecific antibodies and CAR T cells are reshaping relapsed follicular lymphoma care.
- These agents are moving earlier in the treatment sequence and may change sequencing decisions.
Personalize Treatment Decisions
- Tailor therapy to the individual using prior treatments and response duration.
- Consider comorbidities, time since last therapy, and patient preferences when choosing next therapy.
Biology Helps But Isn't Yet Guiding Sequencing
- Tumor biology currently has limited predictive use in routine sequencing decisions.
- Specific mutations like EZH2 help, but broader biology-driven guidance is not yet standard.